Stock Price & Analysis

The S1 support level for PCRX Stock is $23.04 ,The R1 resistant level for PCRX Stock is $26.07.

As of the end of day on 2025-03-10, the price of PCRX Stock was $23.4.

The target price for PCRX Stock according to analyst rating is 32.83, with the highest price target at 50.00 and the lowest at 21.00. Analysts have a Hold rating on PCRX Stock overall.

The market cap of PCRX is $1.1B.

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain, spasticity and stellate ganglion block. The Company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

PCRX has a total of 711 employees.